Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2(+)/HR(−) Trial

PURPOSE: To identify associations of biological signatures and stromal tumor-infiltrating lymphocytes (sTIL) with pathological complete response (pCR; ypT0 ypN0) and survival in the Phase II WSG-ADAPT HER2(+)/HR(−) trial (NCT01817452). EXPERIMENTAL DESIGN: Patients with cT1-cT4c, cN0–3 HER2(+)/HR(−)...

Descripción completa

Detalles Bibliográficos
Autores principales: Graeser, Monika, Gluz, Oleg, Biehl, Claudia, Ulbrich-Gebauer, Daniel, Christgen, Matthias, Palatty, Jenci, Kuemmel, Sherko, Grischke, Eva-Maria, Augustin, Doris, Braun, Michael, Potenberg, Jochem, Wuerstlein, Rachel, Krauss, Katja, Schumacher, Claudia, Forstbauer, Helmut, Reimer, Toralf, Stefek, Andrea, Fischer, Hans Holger, Pelz, Enrico, zu Eulenburg, Christine, Kates, Ronald, Ni, Hua, Kolberg-Liedtke, Cornelia, Feuerhake, Friedrich, Kreipe, Hans Heinrich, Nitz, Ulrike, Harbeck, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932580/
https://www.ncbi.nlm.nih.gov/pubmed/36441798
http://dx.doi.org/10.1158/1078-0432.CCR-22-1587

Ejemplares similares

Ejemplares similares